Equities

Moberg Pharma AB (publ)

Moberg Pharma AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)18.82
  • Today's Change-0.37 / -1.93%
  • Shares traded147.39k
  • 1 Year change+99.15%
  • Beta0.7699
Data delayed at least 15 minutes, as of Nov 22 2024 11:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in SEK

The one analyst offering a 12 month price target expects the share price price of Moberg Pharma AB (publ) to remain relatively unchanged over the next year.
High-1.0%19.00
Med-1.0%19.00
Low-1.0%19.00

Earnings history & estimates in SEK

On Nov 12, 2024, Moberg Pharma AB (publ) reported 3rd quarter 2024 losses of -0.03 per share.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate+60.20%
Annual earnings information is not available for Moberg Pharma AB (publ).
Average growth rate+421.25%
More ▼

Revenue history & estimates in SEK

Moberg Pharma AB (publ) had 3rd quarter 2024 revenues of 3.86m. This missed the 4.00m estimate of the one analyst following the company. The same period last year the company did not report revenues.
Average growth rate+197.46%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.